<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Cambridge Institute for Medical Research</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/28765EA9-5CBF-425D-954B-1ED553D73EB5"><gtr:id>28765EA9-5CBF-425D-954B-1ED553D73EB5</gtr:id><gtr:firstName>Folma</gtr:firstName><gtr:surname>Buss</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK000888%2F1"><gtr:id>401133F5-D913-4A6A-8A06-934FB9A47C19</gtr:id><gtr:title>The myosin VI interactome: the role of motor cargo/adaptor complexes and ubiquitin-binding during selective autophagy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K000888/1</gtr:grantReference><gtr:abstractText>A significant proportion of our ageing population is affected by the late onset of neurodegenerative disorders such as Alzheimer's, motor neuron or Parkinson's diseases. A better understanding of what causes these neurodegenerative diseases could lead to new therapeutic and preventive strategies or could at least improve the quality of life of the affected patients. 
More and more research now suggests that motor neuron disease and some forms of dementia are linked to defects in a cellular pathway that is used to digest abnormal proteins or defective parts of the cell. These defects can lead to an accumulation of these protein as large clumps, which may clog up the transport of essential cargo along nerves in our limbs and eventually cause the nerve cells to die. 
Our research is focused on the special molecular motor protein myosin VI, which drives cargo along tracks in the opposite direction to all other motors to specific sites in the cell, rather like a train running along a railway network to its specific destinations. The cargo is hooked up to the motor with the help of specific adaptor proteins that we have identified in our research. New results now show that this motor protein is present on protein lumps found in nerve cells from patients that died from Alzheimer's disease. Furthermore, it was recently shown that mistakes (mutations) in the protein optineurin, which links myosin VI to specific cargos, causes an inherited form of motor neuron disease. We will thus explore whether myosin VI and optineurin move and dispose of these toxic protein lumps and prevent their accumulation to avoid the death of nerve cells and subsequent neurodegenerative diseases.
We thus hope to identify the precise roles of myosin VI and its adaptor proteins in the pathway that is important for clearance of protein aggregates to keep the nerve cells healthy. This will open up new areas of research that may guide future clinical studies and the development of potential diagnostic tools and possible therapeutic strategies.</gtr:abstractText><gtr:technicalSummary>This research project aims to establish the molecular role of the actin-based motor protein myosin VI in autophagy. In this pathway cytosolic protein aggregates and pathogens are sequestered in autophagosome, which can fuse and deliver its contents to the lysosome for degradation. Neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), Alzheimer's, Huntington's and Parkinson's disease are characterized by the accumulation of intracellular ubiquitin-containing protein aggregates and defects in autophagy can cause neurodegeneration. 
Interestingly, we have identified three myosin VI interacting proteins, NDP52, optineurin and T6BP that can function as autophagy receptors linking ubiquitinated cargo to be degraded to the autophagy machinery. In this process NDP52 and optineurin have been shown to be essential for clearance of pathogens from the cytosol of eukaryotic cells by autophagy and mutations in optineurin have been linked to the familial form of the motor neuron disease (ALS), where optineurin has been identified on SOD-1 and TDP-43 protein aggregates. Intriguingly, myosin VI has also been linked to neurodegeneration, since it was shown to associate with neurofibrillary tau tangles in Alzheimer's disease patients as well as in a transgenic mutant tau mouse. 
Myosin VI is a unique reverse direction myosin motor protein that functions in a wide variety of intracellular processes including cargo sorting and vesicle transport in the endocytic and secretory pathways. In this proposal we will build upon our recently published work on the cellular functions of myosin VI and use our tools together with reagents and knowledge to establish the molecular role of this motor in autophagy for the clearance of protein aggregates and bacterial invaders. We will determine how myosin VI is recruited to autophagosomes and whether dysfunction of this motor affects membrane delivery required for autophagosome biogenesis, maturation or fusion with the lysosome.</gtr:technicalSummary><gtr:potentialImpactText>Who will benefit from this research? 
In addition to the specific academic beneficiaries that have been listed in the section above, the public and wider academic community will benefit from our greater understanding of crucial processes in basic cell biology and motor protein function. Of particular importance and interest for the general public is the increase in knowledge about neurological diseases such as dementia. Brain disorders and neurodegeneration affect a high percentage of our aging population in the UK and places a heavy burden on our health budget. Therefore the outcome from our work will be of interest to a wide range of health professionals. Myosin motor proteins have been shown to be drug targets and we are currently testing new small molecule compounds designed to target specific classes of myosins in our cellular assay systems. Thus sectors of the pharmaceutical industry that develop drugs to treat neurological disorders will be interested in new discoveries and knowledge generated by this work. In the long term patients suffering from neurodegeneration may also benefit and thus there might be a crucial positive impact on improving health, well-being and wealth in the UK. In addition the outcome from this research will improve our knowledge about how myosin motor proteins especially motors like myosin VI function and therefore will have an impact on industries in the bionanotechnology field. It should be emphasized again that myosin VI is unique, since it moves along actin filaments in the reverse direction to all other motors.
How might they benefit from this research? 
1. Health care professionals and patients will benefit from the work undertaken in this study. Although this proposal focuses on the role of a myosin motor protein involved in neurodegeneration, mutations in this motor have also been linked to inherited forms of deafness as well as heart disease and prostate cancer. As mentioned above the social and healthcare costs of these diseases are enormous and therefore any advances in understanding the underlying mechanisms will impact on the treatment of these diseases and the development of disease specific drugs. This will impact on the well-being and quality of life of patients and their immediate social environment. This can create economic benefits by saving health care costs, but also will boost the UK-based pharmaceutical industry.
2. Benefits for Industry: The basic research outlined in this proposal is likely to have a direct impact upon future strategies for treatment. It might directly lead to identification of potential new drug targets for the treatment of neurodegenerative disorders such as motor neuron disease, Alzheimer's and Parkinson's disease. Myosin motor proteins have been proven to be excellent drug targets and therefore to establish whether a myosin motor is involved in autophagy and clearance of protein aggregates leading to neuronal cell death is an important step forward in identifying therapeutic targets. We have close collaborations with Biophysicists and Chemists and are currently testing new small molecules for regulating myosin motor activity. 
3. The General Public will benefit from this research, because it will help our understanding of the causes of disease and will therefore clearly demonstrate the benefits of basic research to the wider general public.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-01-13</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-01-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>501861</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cambridge Science Week</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6789B40F-72E5-448B-8E21-FE50C5F7C663</gtr:id><gtr:impact>For several years the CIMR has taken part in the Cambridge Science Festival (www.cam.ac.uk/science-festival) that takes place for a week in March, during which the Buss lab explains and provides a hands on workstation on muscle, motors and intracellular transport. This is a very popular event and thousands of families attend each year.</gtr:impact><gtr:outcomeId>56d9720123fd48.69739311</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cam.ac.uk/science-festival</gtr:url><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Days at Primary School</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1120BC04-C290-47B3-B413-C004CC160326</gtr:id><gtr:impact>On several occasions students from the Buss lab have also participated in &amp;quot;Science Days&amp;quot; at Fulbourn Primary School, working with children aged 5-8 years on various scientific questions/concepts and Tom O'Loughlin from the Buss lab ran a workshop for international high
school students in Jesus College, Cambridge on cell trafficking, including a talk and microscopy sessions using Paramecium as a life cell model.</gtr:impact><gtr:outcomeId>56d9727618c768.12053714</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>674298</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Council Project Grant</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N000048/1</gtr:fundingRef><gtr:id>7B8D1132-6C1B-4D04-A6B4-26B2FF8597D9</gtr:id><gtr:outcomeId>56d96f27e29648.91210053</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>489582</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Pirbright Institute</gtr:department><gtr:description>BBSRC project grant</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>82D7533C-92DF-4945-80E6-AA01138D54E3</gtr:id><gtr:outcomeId>SnB6P7ALMAp</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>27600</gtr:amountPounds><gtr:country>Ireland, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial Collaboration with Trino Therapeutics</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Trino Therapeutics</gtr:fundingOrg><gtr:id>5931241F-8F0F-480F-9219-5C7DA9902F01</gtr:id><gtr:outcomeId>56d970bf8b6883.23978922</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>221176</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF project grant</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>PG/15/12/31280</gtr:fundingRef><gtr:id>F9C045E6-E179-480F-81A6-5E969921EA92</gtr:id><gtr:outcomeId>56d9702dbe42f8.19996545</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Pilot grant</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>AC5D5936-9660-4BD7-A0C6-33EC8A27C76D</gtr:id><gtr:outcomeId>543fde9faf9f48.50511198</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>87E7BD50-DB95-4A4A-B1C8-999245C7A7DF</gtr:id><gtr:title>Loss of functional MYO1C/myosin 1c, a motor protein involved in lipid raft trafficking, disrupts autophagosome-lysosome fusion.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107bee55b4c4fa7720bb152dca3c0ea0"><gtr:id>107bee55b4c4fa7720bb152dca3c0ea0</gtr:id><gtr:otherNames>Brandstaetter H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>56d96de7541ad6.39546499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9BA8911-4F43-4FAD-ABB9-74C31DE38D7F</gtr:id><gtr:title>Functional roles for myosin 1c in cellular signaling pathways.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d4c94840d4ce6fc4414941e834ca7fd"><gtr:id>8d4c94840d4ce6fc4414941e834ca7fd</gtr:id><gtr:otherNames>Bond LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>pm_23363_23_23022959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05C80AE4-C4C7-4664-A030-85829B4FE882</gtr:id><gtr:title>Myosins, Actin and Autophagy.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d13cbfa1c2e17b03d7503e9b907759f"><gtr:id>2d13cbfa1c2e17b03d7503e9b907759f</gtr:id><gtr:otherNames>Kruppa AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>585d6ee14ab965.18582813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2D32452-CE37-4D69-9CCA-6C9A7BC9EE07</gtr:id><gtr:title>Small-molecule inhibitors of myosin proteins.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d4c94840d4ce6fc4414941e834ca7fd"><gtr:id>8d4c94840d4ce6fc4414941e834ca7fd</gtr:id><gtr:otherNames>Bond LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>pm_23363_23_23256812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6C19803-048D-410D-9F23-79BDC87D312B</gtr:id><gtr:title>Myosin VI and its cargo adaptors - linking endocytosis and autophagy.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e477dc06e25fe48a26b2dd1e2b31447"><gtr:id>0e477dc06e25fe48a26b2dd1e2b31447</gtr:id><gtr:otherNames>Tumbarello DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>pm_23363_23_23781020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A32B0473-4119-4247-91CD-BFB451C9DA6B</gtr:id><gtr:title>MYO6 is targeted byvirulence effectors to trigger PI3-kinase signaling and pathogen invasion into host cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7d7c9dd9837806c55d576b5c8725e20"><gtr:id>d7d7c9dd9837806c55d576b5c8725e20</gtr:id><gtr:otherNames>Brooks AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5a2fd588d59be4.97371098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>152BD65B-C5B6-4C5C-A47F-7AA0CEED3CF7</gtr:id><gtr:title>Correction: The Autophagy Receptor TAX1BP1 and the Molecular Motor Myosin VI Are Required for Clearance of Salmonella Typhimurium by Autophagy.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e477dc06e25fe48a26b2dd1e2b31447"><gtr:id>0e477dc06e25fe48a26b2dd1e2b31447</gtr:id><gtr:otherNames>Tumbarello DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56d96de7ac7a83.64216086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA565D00-061F-4682-9E06-99449FE98B3C</gtr:id><gtr:title>The MYO6 interactome reveals adaptor complexes coordinating early endosome and cytoskeletal dynamics.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b89b477d4ca152fe84e5f22beb7705d"><gtr:id>5b89b477d4ca152fe84e5f22beb7705d</gtr:id><gtr:otherNames>O'Loughlin T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>5a981ea57fecd3.06081751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73358C02-920D-4408-B56C-74C01DF56398</gtr:id><gtr:title>Huntingtin is required for ER-to-Golgi transport and for secretory vesicle fusion at the plasma membrane.</gtr:title><gtr:parentPublicationTitle>Disease models &amp; mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/107bee55b4c4fa7720bb152dca3c0ea0"><gtr:id>107bee55b4c4fa7720bb152dca3c0ea0</gtr:id><gtr:otherNames>Brandstaetter H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1754-8403</gtr:issn><gtr:outcomeId>545a2f16069fc2.28493006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C768B212-0DB7-4562-9E27-B49C35DCE9F2</gtr:id><gtr:title>Myosin VI-Dependent Actin Cages Encapsulate Parkin-Positive Damaged Mitochondria.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d13cbfa1c2e17b03d7503e9b907759f"><gtr:id>2d13cbfa1c2e17b03d7503e9b907759f</gtr:id><gtr:otherNames>Kruppa AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>5a997b40db23f2.38207599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>793BB6D9-8277-49B1-B940-A8F52310AE04</gtr:id><gtr:title>The Autophagy Receptor TAX1BP1 and the Molecular Motor Myosin VI Are Required for Clearance of Salmonella Typhimurium by Autophagy.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e477dc06e25fe48a26b2dd1e2b31447"><gtr:id>0e477dc06e25fe48a26b2dd1e2b31447</gtr:id><gtr:otherNames>Tumbarello DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56d96de784a7f9.00386657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C60AD51-C145-4B52-9EB5-37315955E8B8</gtr:id><gtr:title>Myosin VI small insert isoform maintains exocytosis by tethering secretory granules to the cortical actin.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2b0e8f5c8857f236d2b54a9434953cb"><gtr:id>a2b0e8f5c8857f236d2b54a9434953cb</gtr:id><gtr:otherNames>Tomatis VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>pm_23363_23_23382463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A63E0C5-FA62-4E0B-AAB7-0E763CBE663F</gtr:id><gtr:title>Editorial Overview: Myosins in Review.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd6349dafca57da2eec5862e2850590"><gtr:id>2cd6349dafca57da2eec5862e2850590</gtr:id><gtr:otherNames>Kendrick-Jones J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>588b681c1d94b0.92478282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08442208-AC82-4617-873B-9C7AAA8401BD</gtr:id><gtr:title>Myosins: Domain Organisation, Motor Properties, Physiological Roles and Cellular Functions.</gtr:title><gtr:parentPublicationTitle>Handbook of experimental pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e47dc58568822dd272c839fb27d33dff"><gtr:id>e47dc58568822dd272c839fb27d33dff</gtr:id><gtr:otherNames>Masters TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0171-2004</gtr:issn><gtr:outcomeId>588b682435dc90.78126021</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K000888/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>